Medical-grade silicone: evidence for component buyers
A “medical-grade” label is not approval for a device or an implant. Evaluate the exact material and finished device against its intended use and biological risks.
Start with contact and processing
Define direct or indirect body contact, tissue type, exposure duration, sterilization, cleaning and reuse. FDA describes biocompatibility assessment as a risk-based evaluation; it is not a fixed test panel chosen only by a material name.
Keep quality and biological evidence separate
ISO 10993 evaluation concerns biological safety. A USP Class VI material report cannot by itself establish finished-device safety. ISO 13485 concerns quality management. FDA 21 CFR Part 820 QMSR concerns applicable device manufacturing requirements; Part 211 addresses finished pharmaceuticals, not a general silicone-device certification.
Ask what the report actually covers
Check the sample identity, compound and additives, manufacturing and sterilization conditions, test methods, conclusions and relevance to your finished device. A change of process or use may require further assessment. Reuse of another device’s evidence needs a documented justification.
Before requesting a quote
Send the drawing revision, application, material preference, critical dimensions, annual quantity, delivery market and required evidence. Feasibility, testing, price and timing need written project review.
Buyer questions
Does a tested compound make the finished device biocompatible?
Not automatically. Processing, residues, assembly, sterilization and contact conditions may change the assessment. The responsible device manufacturer must justify the finished-device evaluation.